CVM Stock — CEL-SCI Corp

CEL-SCI Corp (CVM)

Updated October 16, 2026.

CVM is a Stock. Total return is -100.0% over the past 42.9 years.

CEL-SCI Corporation, a clinical-stage biotechnology company, engages in the research and development to treat cancer and other diseases by using the immune system in the United States. The company's lead immunotherapy is Multikine, which has completed Phase III clinical trials for the potential treatment of certain head and neck cancers. It is also developing Ligand Epitope Antigen Presentation System (LEAPS) technology, a patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, parasitic infections, autoimmune conditions, allergies, transplantation rejections, and cancer, as well as to potentially treat rheumatoid arthritis. In addition, the company's LEAP product candidates include CEL-2000; CEL-4000; and CEL-5000 that are in preclinical trials for potential rheumatoid arthritis therapeutic treatments. CEL-SCI Corporation has a strategic partnership with Saudi Arabian Pharma Company for Multikine in the treatment of head and neck cancer. The company was incorporated in 1983 and is headquartered in Vienna, Virginia.

CVM performance

Price and return data through 2026-10-16.

Total return is -100.0% over the past 42.9 years. Over the past year its total return — price change plus distributions reinvested — is -81.3%. Its deepest 1-year drawdown was 89.9%.

CVM key facts

Asset type

Stock

Asset class

Equity

Inception date

12/08/1983

Distribution frequency

None

Last close

$1.79 (as of 2026-10-16)

Market cap

$31,484,287

Average volume

168167.0

Ex-dividend date

08/28/1996

Beta

0.588

Payout ratio

0.0%

Forward P/E

23.0415

EPS

$-1.69

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

CVM risks and drawbacks

The deepest 1-year drawdown on record here is 89.9%.

Who may consider CVM — and who may not

It is a weaker fit for investors who need monthly cash flow (CVM does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on CVM

• All tickers starting with C

Tagged: Healthcare.

Frequently asked questions